Hepatocellular injury in a patient receiving rosiglitazone: A case report

Annals of Internal Medicine

Volumn 132, Issue 2, 2000, Pages 121-124

  Al Salman, Jameela ^a   Arjomand, Heider ^a   Kemp, David G ^a   Mittal, Manoj ^a  

^a EASTON HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVER ENZYME; ROSIGLITAZONE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; CASE REPORT; DRUG MECHANISM; HUMAN; INSULIN SENSITIVITY; LIVER CELL DAMAGE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; VOMITING;

EID: 0033972218     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-2-200001180-00006     Document Type: Article

References (10)

1. Prescribing information for rosiglitazone. Data on file. Philadelphia: Bristol-Myers Squibb Co. SmithKline Beecham Pharmaceutical; May 1999.
2. Salzman A, Patel J. Rosiglitazone therapy is not associated with hepatotoxicity [Abstract]. Diabetes. 1999;48:A95.
3. Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann intern Med. 1998;129:36-8.
4. Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, et al. Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med. 1998;129:38-41.
5. Shibuya A, Watanabe M, Fujita Y, Saigenji K, Kuwao S, Takahashi H, et al. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care. 1998;21:2140-3.
6. Berger S, Strange P. Repaglinide in type 2 diabetes: a randomized, placebo-controlled, double-blind, fixed-dose study. Repaglinide Study Group [Abstract]. Diabetes. 1998;47(Suppl 1):A18.
7. Lee WM. Drug-induced hepatotoxicity N Engl J Med. 1995;333:1118-27.
8. Bernstein D, Tripodi J. Fulminant hepatic failure. Crit Care Clin. 1998;14: 181-97.
9. Farrell GC. Liver disease caused by drugs, anesthetics, and toxins. In: Feldman M, Sleisenger MH, Scharschmidt BF, Klein S, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 6th ed. Philadelphia: WB Saunders; 1998:1221-53.
10. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone [Letter]. N Engl J Med. 1998;338:916-7.